Comparison of formoterol, salbutamol and salmeterol in methacholine-induced severe bronchoconstriction

Politiek, Mathijs J; Boorsma, Martin; Aalbers, Rick

doi:10.1034/j.1399-3003.1999.13e10.x

Cited by 93 publications

(91 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…(5,7,(12)(13) In this study, the mean drop in FEV 1 after the use of methacholine was greater than 30% from baseline values, and most patients presented an FEV 1 lower than 2L, which represents significant bronchoconstriction and the onset of bronchial hyperresponsiveness.…”

Section: Discussionmentioning

confidence: 97%

“…(5,8,(11)(12) However, the use of long-acting β2-agonists for the immediate reversion of bronchoconstriction or for the relief of acute symptoms has not been recommended in any asthma management consensuses or guidelines.…”

Section: Discussionmentioning

confidence: 99%

“…The authors found no significant differences between the two groups. In another study, (12) 17 patients with asthma were randomized to receive, after methacholine-induced bronchoconstriction, 12 µg of dry-powder formoterol, 50 µg of dry-powder salmeterol, or 50 µg of dry-powder salbutamol. There were no statistical differences in the onset of action between salbutamol and formoterol.…”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Eficácia do formoterol na reversão imediata do broncoespasmo

Rubin¹,

Perin

Pelegrin

et al. 2006

J. bras. pneumol.

View full text Add to dashboard Cite

Objective: To evaluate the effectiveness and onset of action of formoterol delivered by dry-powder inhaler in reversing methacholine-induced bronchoconstriction. Methods: Patients presenting a drop in forced expiratory volume in one second > 20% after methacholine inhalation were included. A total of 84 patients were evaluated. All of the participating patients presented respiratory symptoms of unknown origin, which were being investigated. The patients were randomized to receive 200 µg of spray fenoterol (n = 41) or 12 µg of dry-powder inhaler formoterol (n = 43), both administered in order to achieve immediate reversal of methacholine-induced bronchoconstriction. We evaluated the decrease in forced expiratory volume in one second (in relation to the baseline value) after methacholine challenge and the dose of methacholine required to provoke a drop of 20% in forced expiratory volume in one second, as well as the increase in forced expiratory volume in one second (in relation to the baseline value) at five and ten minutes after bronchodilator use. Results: There were no significant differences related to gender, age, weight, height or dose of methacholine required to provoke a drop of 20% in forced expiratory volume in one second. Nor were there any significant differences in terms of baseline or post-methacholine forced expiratory volume in one second. In the fenoterol group, the mean postbronchodilator increase in forced expiratory volume in one second increase was 34% (at five minutes) and 50.1% (at ten minutes), compared with 46.5% (at five minutes) and 53.2% (at ten minutes) in the formoterol group. Conclusion: The bronchodilator effect of formoterol at five and ten minutes after methacholine-induced bronchoconstriction was similar to that of fenoterol. Despite being a longacting bronchodilator, formoterol also has a rapid onset of action, which suggests that it could be employed as a relief medication in cases of bronchoconstriction occurring during asthma attacks.

show abstract

Section: Discussionmentioning

confidence: 97%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Eficácia do formoterol na reversão imediata do broncoespasmo

Rubin¹,

Perin

Pelegrin

et al. 2006

J. bras. pneumol.

View full text Add to dashboard Cite

show abstract

“…The rapid and sustained effects of formoterol on bronchodilation/bronchoprotection are well documented and have been mentioned earlier in this review (39,40). Other positive effects reported with LABAs include a reduction in the airway oedema that can occur during an asthma exacerbation by relaxing the endothelial cells (72), inhibition of the release of bronchoconstrictors, such as histamines, from mast cells (73) and beneficial effects on neutrophilic inflammation (23) (Fig.…”

Section: Safety Of Budesonide/formoterol Maintenance and Reliever Thementioning

confidence: 99%

Budesonide/formoterol for maintenance and reliever therapy in the management of moderate to severe asthma

Humbert

Andersson

Buhl³

2008

Allergy

View full text Add to dashboard Cite

The Global Initiative for Asthma (GINA) guidelines aim at improving asthma control and preventing future risk. For patients with moderate to severe asthma an inhaled corticosteroid (ICS) or an ICS/long‐acting β2‐agonist (LABA) combination with a short‐acting β2‐agonist (SABA) as reliever is recommended. Despite the availability of effective maintenance therapies, a large proportion of patients still fail to achieve guideline‐defined asthma control, and overuse of SABA reliever medication at the expense of ICS is commonly observed. New simplified treatment approaches may offer a solution and assist physicians to achieve overall asthma control. One such treatment approach, which is recommended in the GINA guidelines, is budesonide/formoterol for both maintenance and reliever therapy. This treatment strategy significantly reduces the rate of severe asthma exacerbations compared with ICS/LABA plus SABA and achieves equivalent daily symptom control compared with higher doses of ICS/LABA plus separate SABA for relief. These benefits are achieved at a lower overall steroid load, and budesonide/formoterol maintenance and reliever therapy is well tolerated in patients with moderate to severe asthma. This review discusses current asthma management in patients with moderate to severe disease and examines the evidence for alternative asthma management approaches.

show abstract

“…For asthma and chronic bronchitis, proper use of inhaled bronchodilators can relieve shortness of breath and wheeze. They have been shown to be effective, (10)(11)(12)(13)(14)(15)(16)(17)(18)(19)(20) with a low incidence of adverse events. (10,(15)(16)(17) Therefore, fi rst aid providers should be familiar with the available inhaled bronchodilator and assist when a casualty with asthma or chronic bronchitis is experiencing an acute exacerbation of the condition.…”

Section: Medicalmentioning

confidence: 99%

Guidelines for Bystander First Aid 2016

Pek¹

2017

smedj

View full text Add to dashboard Cite

Cardiac life support is a form of fi rst aid for cardiac emergencies. However, research and evidence in this fi eld is lacking compared with other forms of fi rst aid. Having identifi ed the common emergencies that are encountered in the hospital, based on the available evidence, we have put together what could be an evidence-based approach to the fi rst aid management of some of these common emergencies, viz. breathlessness, chest pain, allergies, stroke, heat injury, poisoning, unconsciousness, seizures, and trauma situations such as bleeding, wounds, contusions, head injury, burns and fractures. Educating the public is the key to developing a fi rst responder bystander. These guidelines could become the basis for training of the public.

show abstract

Comparison of formoterol, salbutamol and salmeterol in methacholine-induced severe bronchoconstriction

Cited by 93 publications

References 17 publications

Eficácia do formoterol na reversão imediata do broncoespasmo

Eficácia do formoterol na reversão imediata do broncoespasmo

Budesonide/formoterol for maintenance and reliever therapy in the management of moderate to severe asthma

Guidelines for Bystander First Aid 2016

Contact Info

Product

Resources

About